X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ORCHID PHARMA LTD - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES ORCHID PHARMA LTD DIVIS LABORATORIES/
ORCHID PHARMA LTD
 
P/E (TTM) x 33.1 0.2 17,520.5% View Chart
P/BV x 5.4 0.2 2,401.9% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 DIVIS LABORATORIES   ORCHID PHARMA LTD
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
ORCHID PHARMA LTD
Sep-13
DIVIS LABORATORIES/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs1,222194 629.9%   
Low Rs78435 2,240.0%   
Sales per share (Unadj.) Rs153.1276.5 55.4%  
Earnings per share (Unadj.) Rs39.9-79.2 -50.4%  
Cash flow per share (Unadj.) Rs44.6-43.5 -102.6%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs201.853.9 374.2%  
Shares outstanding (eoy) m265.4770.45 376.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.60.4 1,581.8%   
Avg P/E ratio x25.1-1.4 -1,737.0%  
P/CF ratio (eoy) x22.5-2.6 -853.6%  
Price / Book Value ratio x5.02.1 234.1%  
Dividend payout %25.00-   
Avg Mkt Cap Rs m266,2668,067 3,300.9%   
No. of employees `0009.72.8 347.7%   
Total wages/salary Rs m4,6872,527 185.5%   
Avg. sales/employee Rs Th4,175.06,956.1 60.0%   
Avg. wages/employee Rs Th481.5902.5 53.4%   
Avg. net profit/employee Rs Th1,089.3-1,993.0 -54.7%   
INCOME DATA
Net Sales Rs m40,64319,477 208.7%  
Other income Rs m749407 183.9%   
Total revenues Rs m41,39219,884 208.2%   
Gross profit Rs m14,4601,103 1,311.5%  
Depreciation Rs m1,2332,519 49.0%   
Interest Rs m235,227 0.4%   
Profit before tax Rs m13,953-6,236 -223.7%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m3,349-125 -2,675.1%   
Profit after tax Rs m10,604-5,580 -190.0%  
Gross profit margin %35.65.7 628.5%  
Effective tax rate %24.02.0 1,195.6%   
Net profit margin %26.1-28.7 -91.1%  
BALANCE SHEET DATA
Current assets Rs m40,10511,014 364.1%   
Current liabilities Rs m6,59532,060 20.6%   
Net working cap to sales %82.5-108.1 -76.3%  
Current ratio x6.10.3 1,770.2%  
Inventory Days Days11995 124.9%  
Debtors Days Days8134 240.5%  
Net fixed assets Rs m19,99529,440 67.9%   
Share capital Rs m531705 75.4%   
"Free" reserves Rs m53,0432,043 2,596.8%   
Net worth Rs m53,5743,800 1,409.9%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m61,58546,510 132.4%  
Interest coverage x618.4-0.2 -320,219.0%   
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x0.70.4 157.6%   
Return on assets %17.3-0.8 -2,270.3%  
Return on equity %19.8-146.9 -13.5%  
Return on capital %26.1-3.7 -698.5%  
Exports to sales %037.9 0.0%   
Imports to sales %25.222.6 111.6%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs m10,2594,406 232.8%   
Fx inflow Rs m35,3847,513 470.9%   
Fx outflow Rs m10,3995,649 184.1%   
Net fx Rs m24,9851,865 1,340.0%   
CASH FLOW
From Operations Rs m11,4931,682 683.4%  
From Investments Rs m-11,372-9,860 115.3%  
From Financial Activity Rs m-936,644 -1.4%  
Net Cashflow Rs m28-1,535 -1.9%  

Share Holding

Indian Promoters % 52.0 32.3 161.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 4.6 256.5%  
FIIs % 19.0 3.3 575.8%  
ADR/GDR % 0.0 4.6 -  
Free float % 17.2 55.3 31.1%  
Shareholders   31,796 84,811 37.5%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   WYETH LTD  IPCA LABS  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; Metal Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jun 20, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - SUVEN LIFE COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS